The role of calcium and the L-type calcium channel in pathological remodeling of the heart

Vascular Disease Prevention

Volumn 5, Issue 2, 2008, Pages 104-115

  Viola, Helena M ^b   Hool, Livia C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b NONE

Author keywords

Calcium; Hypertrophy; L type Ca2+ channel; Remodeling; Signaling

Indexed keywords

CALCINEURIN; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE C; PROTEIN KINASE D; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NFAT;

CALCIUM HOMEOSTASIS; DEATH; DISEASE COURSE; HEART FAILURE; HEART FUNCTION; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTROPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 43049087391     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008784223909     Document Type: Review

References (108)

1. Hool LC. What cardiologists should know about calcium ion channels and their regulation by reactive oxygen species. Heart Lung Circ 2007; 16: 361-72.
2. Hool LC, Corry B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal 2007; 9: 409-35.
3. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest 2005; 115: 3306-17.
4. Cooper G, 4th. Cardiocyte adaptation to chronically altered load. Annu Rev Physiol 1987; 49: 501-18.
5. Mondry A, Swynghedauw B. Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Eur Heart J 1995; 16 (Suppl I): 64-73.
6. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
7. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 2002; 541: 1-8.
8. Berridge MJ. Calcium microdomains: organization and function. Cell Calcium 2006; 40: 405-12.
9. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, Swynghedauw B. Myosin isoenzyme redistribution in chronic heart overload. Nature 1979; 282: 105-7.
10. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837-49.
11. Berridge MJ. Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem Soc Trans 2006; 34: 228-31.
12. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996; 76: 631-49.
13. Jayaraman T, Brillantes AM, Timerman AP, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992; 267: 9474-7.
14. Timerman AP, Onoue H, Xin HB, et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem 1996; 271: 20385-91.
15. Xin HB, Senbonmatsu T, Cheng DS, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 2002; 416: 334-8.
16. Kirchhefer U, Neumann J, Baba HA, et al. Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1. J Biol Chem 2001; 276: 4142-9.
17. Balke CW, Shorofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 1998; 37: 290-9.
18. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004; 322: 1178-91.
19. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 2004; 63: 487-99.
20. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47: 23-37.
21. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115: 527-37.
22. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 1995; 270: 28495-8.
23. Wang J, Liu X, Arneja AS, Dhalla NS. Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy. Can J Cardiol 1999; 15: 683-90.
24. McKinsey TA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res 2007; 73: 667-77.
25. Malhotra A, Kang BP, Opawumi D, Belizaire W, Meggs LG. Molecular biology of protein kinase C signaling in cardiac myocytes. Mol Cell Biochem 2001; 225: 97-107.
26. Poole AW, Pula G, Hers I, Crosby D, Jones ML. PKC-interacting proteins: from function to pharmacology. Trends Pharmacol Sci 2004; 25: 528-35.
27. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28.
28. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000; 97: 1196-201.
29. Wilkins BJ, De Windt LJ, Bueno OF, et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 2002; 22: 7603-13.
30. Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 2006; 27: 317-23.
31. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci U S A 1997; 94: 9320-5.
32. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997; 100: 2189-95.
33. Roman BB, Geenen DL, Leitges M, Buttrick PM. PKC-beta is not necessary for cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2001; 280: H2264-70.
34. Sentex E, Wang X, Liu X, Lukas A, Dhalla NS. Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload. Can J Physiol Pharmacol 2006; 84: 227-38.
35. Harrison BC, Kim MS, van Rooij E, et al. Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol 2006; 26: 3875-88.
36. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26L-40L.
37. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80: 7L-14L.
38. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346: 1357-65.
39. Boluyt MO, Long X, Eschenhagen T, et al. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol 1995; 269: H638-47.
40. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001; 98: 3328-33.
41. Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 2006; 291: H1299-308.
42. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005; 11: 409-17.
43. Gruver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology 1993; 133: 376-88.
44. Ramirez MT, Zhao XL, Schulman H, Brown JH. The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem 1997; 272: 31203-8.
45. Colomer JM, Means AR. Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. Mol Endocrinol 2000; 14: 1125-36.
46. Iwata M, Maturana A, Hoshijima M, et al. PKCepsilon-PKD1 signaling complex at Z-discs plays a pivotal role in the cardiac hypertrophy induced by G-protein coupling receptor agonists. Biochem Biophys Res Commun 2005; 327: 1105-13.
47. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J 1996; 15: 6220-30.
48. Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004; 24: 8374-85.
49. Yamazaki T, Tobe K, Hoh E, et al. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes. J Biol Chem 1993; 268: 12069-76.
50. Yamazaki T, Komuro I, Zou Y, et al. Protein kinase A and protein kinase C synergistically activate the Raf-1 kinase/mitogen-activated protein kinase cascade in neonatal rat cardiomyocytes. J Mol Cell Cardiol 1997; 29: 2491-501.
51. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000; 19: 6341-50.
52. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001; 20: 2757-67.
53. Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161-8.
54. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6: 556-63.
55. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71: 208-15.
56. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-88.
57. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-8.
58. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1005-28.
59. Viola HM, Arthur PG, Hool LC. Transient exposure to hydrogen peroxide causes an increase in mitochondria-derived superoxide as a result of sustained alteration in L-type Ca2+ channel function in the absence of apoptosis in ventricular myocytes. Circ Res 2007; 100: 1036-44.
60. Hool LC, Di Maria CA, Viola HM, Arthur PG. Role of NAD(P)H oxidase in the regulation of cardiac L-type Ca2+ channel function during acute hypoxia. Cardiovasc Res 2005; 67: 624-35.
61. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5: 731-40.
62. Bolli R. Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res Cardiol 1998; 93: 156-62.
63. Grieve DJ, Byrne JA, Cave AC, Shah AM. Role of oxidative stress in cardiac remodelling after myocardial infarction. Heart Lung Circ 2004; 13: 132-8.
64. Hool LC. Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels. Clin Exp Pharmacol Physiol 2006; 33: 146-51.
65. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000; 192: 1001-14.
66. Bernardi P, Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 1996; 28: 131-8.
67. Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1998; 1366: 33-50.
68. Aon MA, Cortassa S, Marban E, O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem 2003; 278: 44735-44.
69. Antunes F, Cadenas E. Estimation of H2O2 gradients across biomembranes. FEBS Lett 2000; 475: 121-6.
70. Hool LC. Hypoxia increases the sensitivity of the L-type Ca(2+) current to beta-adrenergic receptor stimulation via a C2 region-containing protein kinase C isoform. Circ Res 2000; 87: 1164-71.
71. Hool LC, Arthur PG. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the Ltype Ca2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res 2002; 91: 601-9.
72. Bodi I, Muth JN, Hahn HS, et al. Electrical remodeling in hearts from a calcium-dependent mouse model of hypertrophy and failure: complex nature of K+ current changes and action potential duration. J Am Coll Cardiol 2003; 41: 1611-22.
73. Zobel C, Rana OR, Saygili E, et al. Mechanisms of Ca2+-dependent calcineurin activation in mechanical stretch-induced hypertrophy. Cardiology 2007; 107: 281-90.
74. Campbell DL, Stamler JS, Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 1996; 108: 277-93.
75. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364: 626-32.
76. Gilbert HF. Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Relat Areas Mol Biol 1990; 63: 69-172.
77. Hool LC. Hypoxia alters the sensitivity of the L-type Ca(2+) channel to alpha-adrenergic receptor stimulation in the presence of beta-adrenergic receptor stimulation. Circ Res 2001; 88: 1036-43.
78. Fearon IM, Palmer AC, Balmforth AJ, Ball SG, Varadi G, Peers C. Modulation of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by redox agents and hypoxia. J Physiol 1999; 514 (Pt 3): 629-37.
79. Sims C, Harvey RD. Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2+) channel activity by phenylarsine oxide. Br J Pharmacol 2004; 142: 797-807.
80. Akaishi T, Nakazawa K, Sato K, Saito H, Ohno Y, Ito Y. Hydrogen peroxide modulates whole cell Ca2+ currents through L-type channels in cultured rat dentate granule cells. Neurosci Lett 2004; 356: 25-8.
81. Jeroudi MO, Hartley CJ, Bolli R. Myocardial reperfusion injury: role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol 1994; 73: 2B-7B.
82. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-37.
83. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001; 132: 159-64.
84. Hu TP, Xu FP, Li YJ, Luo JD. Simvastatin inhibits leptin-induced hypertrophy in cultured neonatal rat cardiomyocytes. Acta Pharmacol Sin 2006; 27: 419-22.
85. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-7.
86. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007; 115: 144-50.
87. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
88. Gokce N, Keaney JF, Jr., Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-72.
89. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-5A.
90. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
91. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
92. Kaab S, Dixon J, Duc J, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998; 98: 1383-93.
93. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005; 85: 1205-53.
94. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-30.
95. van Rooij E, Doevendans PA, de Theije CC, Babiker FA, Molkentin JD, de Windt LJ. Requirement of nuclear factor of activated Tcells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 2002; 277: 48617-26.
96. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 2003; 92: 725-31.
97. Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 2005; 25: 865-78.
98. De Windt LJ, Lim HW, Bueno OF, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2001; 98: 3322-7.
99. Zou Y, Hiroi Y, Uozumi H, et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 2001; 104: 97-101.
100. Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 2002; 277: 10251-5.
101. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002; 99: 907-12.
102. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci USA 2002; 99: 4586-91.
103. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003; 92: 609-16.
104. Vega RB, Rothermel BA, Weinheimer CJ, et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci USA 2003; 100: 669-74.
105. van Rooij E, Doevendans PA, Crijns HJ, et al. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res 2004; 94: e18-26.
106. Wilkins BJ, Dai YS, Bueno OF, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004; 94: 110-8.
107. Khoo MS, Li J, Singh MV, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006; 114: 1352-9.
108. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J 2006; 20: 1660-70.